Էջ 1 սկսած 42 արդյունքներ
TECHNICAL FIELD
The present invention relates to O.sup.6 -substituted guanine derivatives, a process for their preparation and their use in treating tumour cells. In particular, it relates to guanine derivatives having hetarylalkyl or naphthylalkyl substituents in the O.sup.6 position, these
TECHNICAL FIELD
The present invention relates to pyrimidine derivatives and guanine derivatives, and their use in treating tumour cells. In particular, it relates to 6-hetarylalkyloxy pyrimidine derivatives, O.sup.6 -substituted guanine derivatives and S.sup.6 -substituted thioguanine derivatives,
The work herein was supported, in part, by grants from the United States Government. The United States Government may have certain rights in the invention.
BACKGROUND OF THE INVENTION
Guanine-rich oligonucleotides can spontaneously self-assemble into four-stranded helices in vitro (Sen, D. &
This application is a National Stage Application of PCT/JP2003/010449, filed Aug. 19, 2003 and claims priority from Japanese Patent Application No. 2002-382083, filed Nov. 24, 2002, which is incorporated herein by reference in its entirety.
TECHNICAL FIELD
The present invention relates to a method
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a National Stage of PCT/EP2010/052894, filed Mar. 8, 2010 which claims priority to European Patent No. 09154527.7, filed Mar. 6, 2009, the disclosures of which are incorporated herein by reference in their entirety.
SEQUENCE LISTING
The
FIELD OF THE INVENTION
The present invention relates to the production of monoclonal antibodies specific for human O.sup.6 -guanine alkyltransferase, and the use of such MAbs in an immunopurification process which permits the recovery of a homogenous protein product.
BACKGROUND OF THE
BACKGROUND
In 2007 it was reported that over half a million people died from cancer and more than 1.4 million new cases were diagnosed in the United States. Thus, it is important to diagnose, assess prognosis for, and monitor treatment of cancer. Improved, noninvasive diagnostic compositions and
TECHNICAL FIELD OF THE INVENTION
The present invention relates to substituted O.sup.6 -benzylguanines, O.sup.6 -benzyl-8-azaguanines, and 6(4)-benzyloxypyrimidines, pharmaceutical compositions comprising such compounds, and-methods of using such compounds. The subject compounds are particularly
BACKGROUND OF THE INVENTION
Certain guanine-N-oxides, particularly the N.sup.1 -, N.sup.3 -, and N.sup.9 -oxides have been known in the literature for some time. G. B. Brown and his co-workers have conducted a series of studies on guanine-N-oxides.
In 1965, Brown, et al. [Cancer Research, 25:986-991
FIELD OF THE INVENTION
The present invention relates to O.sup.6 -substituted guanine derivatives which possess the ability to deplete O.sup.6 -alkylguanine-DNA alkyltransferase (AGT) activity in vitro and in vivo and to methods for the administration thereof to enhance the chemotherapeutic treatment
TECHNICAL FIELD OF THE INVENTION
The present invention relates to substituted O.sup.6 -benzylguanines and 6(4)-benzyloxypyrimidines, pharmaceutical compositions comprising such compounds, and methods of using such compounds. The subject compounds are particularly useful in inactivating the human DNA
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to O.sup.6 -benzyl-substituted guanine compounds which exhibit the ability to deplete O.sup.6 -alkylguanine-DNA alkyltransferase (AGT) activity and to methods for the administration thereof to enhance
FIELD OF THE INVENTION
The present invention relates to O.sup.6 -benzylated guanine, guanosine and 2'-deoxyguanosine compounds which possess the ability to deplete O.sup.6 -alkylguanine-DNA alkyltransferase (AGT) activity in vivo, and to methods for the administration thereof to enhance
The present invention relates to the field of inhibiting cellular proliferation. More specifically, the present invention relates to methods and compositions for inhibiting cell proliferation and growth and inducing cell death comprising the administration of compositions comprising
FIELD OF INVENTION
This invention relates to compounds useful for inhibiting telomere elongation. More specifically, the invention provides nucleotide analogs that are incorporated into telomeres by telomerase thereby inhibiting elongation of telomeres. The compounds are useful in treating cancer